# Enliven Therapeutics, Inc. (ELVN)

> Source: Nexqual · https://nexqual.com/ELVN · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, Enliven Therapeutics, Inc. (ELVN), nexqual.com/ELVN" · informational, not investment advice.

**Price:** USD 44.78 (+2.50% on the day) · last close of Oct 28, 2026; US market closed, not a live price. Prev close 44.78 · day 43.39–44.94 · 52w 14.79–62.32 · market cap null · NMS

## Key facts
- Insider open-market sales, last ~7 months: 18 Form 4 filings, $65.8M; 3 not under a Rule 10b5-1 plan ($52.3M); 5 by opportunistic insiders (0 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Next earnings: 2026-11-11, EPS estimate USD -0.45, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$51.4M | -$38.8M | -$83.5M | -$105M | -$120M | -$124M |
| Net income | -$51.4M | -$37.7M | -$71.6M | -$89.0M | -$104M | -$106M |
| EPS (diluted) | -$2.37 | -$12.05 | -$2.01 | -$1.89 | -$1.83 | — |
| Free cash flow | -$46.8M | -$32.7M | -$61.4M | -$73.2M | -$70.5M | -$67.0M |
| Cash + short-term investments | $90.3M | $75.5M | $253M | $313M | $463M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)


## Insider sales (SEC Form 4, open-market, last ~7 months)
15 of 18 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 6,018 | $232K | 13.7% | Yes (adopted March 18, 2026) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-10-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 | $192K | 16.7% | Yes (adopted October 19, 2025) | Too little history (no open-market trades in 2023 or 2025) |
| 2026-10-01 | Garland J. Scott | Director | 13,000 | $607K | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 6,018 | $303K | 13.7% | Yes (adopted March 18, 2026) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-09-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 | $252K | 16.7% | Yes (adopted October 19, 2025) | Too little history (no open-market trades in 2023 or 2025) |
| 2026-08-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 6,018 | $353K | 13.1% | Yes (adopted March 18, 2026) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 | $293K | 16.7% | Yes (adopted October 19, 2025) | Too little history (no open-market trades in 2023 or 2025) |
| 2026-08-04 | Derynck Mika K | Director | 158,795 | $9.6M | 100% | Yes (adopted April 8, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-07-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 6,018 | $317K | 11.6% | Yes (adopted March 18, 2026) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-07-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 | $263K | 16.7% | Yes (adopted October 19, 2025) | Too little history (no open-market trades in 2023 or 2025) |
| 2026-07-06 | Kunkel Lori Anne | Director | 10,000 | $505K | 19.3% | Yes (adopted March 6, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22 | Orbimed Advisors Llc |  | 860,123 | $39.0M | 11.6% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 6,018 | $264K | 10.6% | Yes (adopted March 18, 2026) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 | $219K | 16.7% | Yes (adopted October 19, 2025) | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-15 | Orbimed Advisors Llc |  | 281,408 | $12.7M | 3.7% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-05 | Kunkel Lori Anne | Director | 10,000 | $345K | 16.2% | Yes (adopted March 6, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-05-18 | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 | $199K | 16.7% | Yes (adopted October 19, 2025) | Too little history (no open-market trades in 2023 or 2025) |
| 2026-04-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 | $238K | 16.7% | Yes (adopted October 19, 2025) | Too little history (no open-market trades in 2023 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | HC Wainwright & Co. | Target raised | Buy | $65 → $73 |
| 2026-10-02 | Morgan Stanley | Initiated | Overweight | $70 |
| 2026-10-01 | JP Morgan | Initiated | Overweight | $75 |
| 2026-08-18 | William Blair | Initiated | Outperform |  |
| 2026-08-18 | Barclays | Initiated | Overweight | $78 |
| 2026-08-18 | Mizuho | Target raised | Outperform | $62 → $73 |
| 2026-08-06 | Stifel | Target raised | Buy | $80 → $82 |
| 2026-08-06 | Guggenheim | Target lowered | Buy | $80 → $78 |
| 2026-08-06 | Goldman Sachs | Target raised | Buy | $67 → $80 |
| 2026-07-21 | Goldman Sachs | Target raised | Buy | $59 → $67 |
| 2026-07-09 | HC Wainwright & Co. | Target raised | Buy | $56 → $64 |
| 2026-07-01 | Stifel | Target raised | Buy | $60 → $80 |

## More
Full page: https://nexqual.com/ELVN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.45 | $-0.43 | −$0.02 | $0 | 8 |
| Next quarter (ends 2026-12-31) | $-0.57 | $-0.54 | −$0.03 | $0 | 7 |
| Current fiscal year (ends 2026-12-31) | $-1.91 | $-1.70 | −$0.22 | $0 | 8 |
| Next fiscal year (ends 2027-12-31) | $-2.32 | $-2.33 | +$0.01 | $5,000 | 8 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.49 | −$0.38 | Miss −28.9% | — |
| — | Quarter ended Mar 31, 2026 | −$0.38 | −$0.41 | Beat +7.3% | — |
| — | Quarter ended Dec 31, 2025 | −$0.48 | −$0.47 | Miss −2.1% | — |
| — | Quarter ended Sep 30, 2025 | −$0.32 | −$0.46 | Beat +30.4% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-27 | Schedule 13G/A | BlackRock, Inc.: 7.1% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1672619/000201238326003776/0002012383-26-003776-index.htm |
| 2026-10-14 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure — “Appointment of Director On October 14, 2026, the board of directors (the "Board") of Enliven Therapeutics, Inc. (the "Company") increased the size of the Board from seven to eight directors and appointed Kristine Ball to serve as a Class II director, with a term expiring at the Company's 2028 annual meeting of stockholders, and as a member of the Audit Committee of the Board (the "Audit Committee"), effective October 14, 2026. There are no transactions in which Ms. Ball has an interest that would require…” | https://www.sec.gov/Archives/edgar/data/1672619/000119312526421761/0001193125-26-421761-index.htm |
| 2026-08-06 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 15.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1672619/000031506626001988/0000315066-26-001988-index.htm |
| 2026-08-05 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1672619/000119312526335155/0001193125-26-335155-index.htm |
| 2026-08-05 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1672619/000119312526335101/0001193125-26-335101-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.